MARGENZA
Drug
MACROGENICS, INC.
Total Payments
$4.7M
Transactions
1,172
Doctors
389
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $866.83 | 13 | 12 |
| 2023 | $361,600 | 141 | 106 |
| 2022 | $1.8M | 660 | 239 |
| 2021 | $2.5M | 358 | 76 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.7M | 696 | 99.0% |
| Honoraria | $26,778 | 20 | 0.6% |
| Food and Beverage | $11,857 | 447 | 0.3% |
| Consulting Fee | $7,300 | 9 | 0.2% |
Payments by Type
Research
$4.7M
696 transactions
General
$45,935
476 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT | MACROGENICS, INC. | $1.6M | 0 |
| COMBINATION MARGETUXIMAB, INCMGA00012, MGD013, AND CHEMOTHERAPY PHASE 2 3 TRIAL IN HER2 GASTRIC GEJ CANCER MAHOGANY | MACROGENICS, INC. | $1.0M | 0 |
| NEOADJUVANT PACLITAXEL MARGETUXIMAB PERTUZUMAB COMPARED TO PACLITAXEL TRASTUZUMAB PERTUZUMAB FOR PATIENTS WITH ANATOMIC STAGE II-IIII HER2-POSITIVE BREAST CANCER A RANDOMIZED PHASE II TRIAL | MACROGENICS, INC. | $886,640 | 0 |
| A PHASE 1B 2, OPEN LABEL, DOSE ESCALATION STUDY OF MARGETUXIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED REFRACTORY ADVANCED HER2 GASTROESOPHAGEAL JUNCTION OR GASTRIC CANCER | MACROGENICS, INC. | $403,758 | 0 |
| A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT | MacroGenics, Inc. | $303,060 | 0 |
| COMBINATION MARGETUXIMAB, INCMGA00012, MGD013, AND CHEMOTHERAPY PHASE 2 3 TRIAL IN HER2 GASTRIC GEJ CANCER MAHOGANY | MacroGenics, Inc. | $269,031 | 0 |
| A PHASE 1 2, FIRST IN HUMAN, DOSE ESCALATION STUDY OF MGD006, A CD123 X CD3 DART BI-SPECIFIC ANTIBODY BASED MOLECULE, IN PATIENTS WITH RELAPSED OR REFRACTORY AML OR INTERMEDIATE-2 HIGH RISK MYELODYSPLASTIC SYNDROME MDS | MACROGENICS, INC. | $103,102 | 0 |
| A PHASE 1, DOSE ESCALATION STUDY OF MGAH22 IN PATIENTS WITH REFRACTORY HER2 POSITIVE BREAST CANCER AND PATIENTS WITH OTHER HER2 POSITIVE CARCINOMAS FOR WHOM NO STANDARD THERAPY IS AVAILABLE | MACROGENICS, INC. | $59,746 | 0 |
| A PHASE 1B 2, OPEN LABEL, DOSE ESCALATION STUDY OF MARGETUXIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED REFRACTORY ADVANCED HER2 GASTROESOPHAGEAL JUNCTION OR GASTRIC CANCER | MacroGenics, Inc. | $47,453 | 2 |
| A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT | MACROGENICS, INC. | $27,390 | 0 |
| A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT | MacroGenics, Inc. | $1,600 | 0 |
Top Doctors Receiving Payments for MARGENZA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Jacksonville, FL | $93.11 | 1 |
| , M.D | Hematology & Oncology | Jacksonville, FL | $93.11 | 1 |
| , M.D | Internal Medicine | Albuquerque, NM | $91.01 | 1 |
| , MD | Internal Medicine | Albuquerque, NM | $91.01 | 1 |
| , MD | Internal Medicine | Paducah, KY | $80.57 | 4 |
| , M.D | Internal Medicine | Los Angeles, CA | $76.20 | 1 |
| , MD | Medical Oncology | New York, NY | $75.42 | 1 |
| , MD PHD | Hematology & Oncology | Golden, CO | $73.04 | 3 |
| , M.D | Gynecologic Oncology | Houston, TX | $72.19 | 1 |
| , MD, MPH, MS | Gynecologic Oncology | Houston, TX | $72.19 | 1 |
| , NP | Nurse Practitioner | North Bergen, NJ | $70.83 | 4 |
| , MD | Medical Oncology | Denver, CO | $65.17 | 3 |
| , MD | Internal Medicine | Washington, DC | $65.14 | 1 |
| , MD, PHD | Hematology & Oncology | Los Angeles, CA | $65.14 | 1 |
| , M.D., PHD | Hematology & Oncology | Houston, TX | $65.14 | 1 |
| , MD | Medical Oncology | Charlottesville, VA | $65.14 | 1 |
| Ana Aparicio | Hematology & Oncology | Houston, TX | $65.14 | 1 |
| , MD, PHD | Medical Oncology | Houston, TX | $65.14 | 1 |
| , M.D | Medical Oncology | Washington, DC | $65.14 | 1 |
| , M.D | Medical Oncology | Baltimore, MD | $65.14 | 1 |
| , M.D | Internal Medicine | Boston, MA | $65.14 | 1 |
| , M.D | Hematology & Oncology | Beverly Hills, CA | $62.72 | 2 |
| , M.D | Hematology & Oncology | Beverly Hills, CA | $62.72 | 2 |
| , M.D | Specialist | Paducah, KY | $60.28 | 3 |
| , MD | Hematology & Oncology | Tampa, FL | $58.72 | 3 |
Ad
Manufacturing Companies
- MACROGENICS, INC. $4.1M
- MacroGenics, Inc. $621,145
Product Information
- Type Drug
- Total Payments $4.7M
- Total Doctors 389
- Transactions 1,172
About MARGENZA
MARGENZA is a drug associated with $4.7M in payments to 389 healthcare providers, recorded across 1,172 transactions in the CMS Open Payments database. The primary manufacturer is MACROGENICS, INC..
Payment data is available from 2021 to 2024. In 2024, $866.83 was paid across 13 transactions to 12 doctors.
The most common payment nature for MARGENZA is "Unspecified" ($4.7M, 99.0% of total).
MARGENZA is associated with 11 research studies, including "A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT" ($1.6M).